- Global Pharma News & Resources

Growth Hormone Antagonist - Pipeline Insight 2018 -

The "Growth Hormone Antagonist -Pipeline Insight, 2018" drug pipelines has been added to's offering.

Growth Hormone Antagonist - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Growth Hormone Antagonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Growth Hormone Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Growth Hormone Antagonist - Overview

3. Pipeline Therapeutics4. Comparative Analysis

5. Growth Hormone Antagonist Pipeline Products in Clinical Stages

6. Growth Hormone Antagonist Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

Companies Mentioned

  • Biscayne Pharmaceuticals
  • Italfarmaco
  • Ipsen
  • Chiasma
  • Novartis
  • Peptron
  • GlaxoSmithKline

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 21-Dec-2018